One test for complete patient management
ThyroSeq utilizes next-generation DNA and RNA sequencing to accurately identify thyroid nodules as benign, low-risk cancer or high-risk cancer. Rule out preventable surgeries and improve clinical outcomes for patients with thyroid cancer with the ThyroSeq test.
Why Use The ThyroSeq Test
Molecular testing aids in management of thyroid nodules which are indeterminate by cytology. In one test, ThyroSeq:
Confidently rules out cancer and prevents unneeded surgeries in 63-73% of patients with indeterminate-cytology thyroid nodules1-5
Provides granular probability of cancer, predicts tumor type and risk of recurrence
Detects pre-operatively all types of thyroid cancer (papillary, follicular, oncocytic, medullary) and non-thyroidal lesions (parathyroid, metastases to the thyroid)
Detects all targetable alterations in advanced thyroid cancer to support selection of FDA-approved targeted therapies
Guides personalized patient management including surgical plan and post-surgical treatment
ThyroSeq molecular testing has empowered more than 150,000 patients and their care teams to make informed treatment decisions – leading to better outcomes and improved quality of life.
How can the ThyroSeq test help you?
Stay Connected with ThyroSeq
This form is for US healthcare providers. Sign up to receive updates, information, and resources.
References
- Guan H, et al. Thyroid. 2020 Apr;30(4):536-547.
- Desai D, et al. Cancer Cytopathol. 2021 Feb;129(2):164-170.
- Gajzer DC, et al. Cancer Cytopathol. 2022 Nov;130(11):881-890.
- Nachum S, et al. Thyroid. 2025 Mar;35(3):265-273.
- Lévesque F, et al. J Clin Endocrinol Metab. 2025 Mar 17;110(4):e1031-e1037.